DESSCIPHER
To decipher the optimal management of systemic sclerosis
| Coordinatore | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Organization address
address: Ludwigstrasse 23 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙791˙344 € |
| EC contributo | 2˙999˙835 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Organization address
address: Ludwigstrasse 23 contact info |
DE (GIESSEN) | coordinator | 555˙182.21 |
| 2 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 550˙206.80 |
| 3 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 502˙795.30 |
| 4 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 218˙070.80 |
| 5 |
Nome Ente NON disponibile
Organization address
address: VIALE BENEDUCE 10 contact info |
IT (CASERTA) | participant | 185˙840.00 |
| 6 |
UNIVERSITAET BASEL
Organization address
address: Petersplatz 1 contact info |
CH (BASEL) | participant | 170˙919.49 |
| 7 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 168˙998.00 |
| 8 |
PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS
Organization address
address: VASVARI PAL UTCA 4 contact info |
HU (PECS) | participant | 152˙520.00 |
| 9 |
NEW-WIN AG
Organization address
address: TRAMSTRASSE 7 contact info |
CH (SUHR) | participant | 121˙500.00 |
| 10 |
UNIVERSITE PARIS DESCARTES
Organization address
address: Rue de l'Ecole de Medecine 12 contact info |
FR (PARIS) | participant | 110˙224.00 |
| 11 |
UNIVERSITA DEGLI STUDI DI FIRENZE
Organization address
address: Piazza San Marco 4 contact info |
IT (Florence) | participant | 104˙440.00 |
| 12 |
ACIES Consulting Group SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 89˙920.00 |
| 13 |
FEDERATION OF EUROPEAN SCLERODERMA ASSOCIATIONS AISBL
Organization address
address: "LE VERSAILLES, AVENUE DES ETATS-UNIS 20, BOITE 32" contact info |
BE (TOURNAI) | participant | 36˙978.40 |
| 14 |
IVAN FOELDVARI
Organization address
address: LANGE REIHE 83 contact info |
DE (HAMBURG) | participant | 32˙240.00 |
| 15 |
NOVAMEN SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The current approach to diagnosis and management of the rare disease systemic sclerosis (SSc) is based on American College of Rheumatology criteria with low sensitivity and few validated recommendations for the therapy of the disease and its manifold organ manifestations. To overcome these shortcomings, the DeSScipher project will use the multinational, prospective and open EUSTAR (Scleroderma Trials and Research group of the European League Against Rheumatism) SSc cohort based on the established MEDSonline database which covers >30 data items and will evolve into a multimodular tool to answer step-by-step all immanent questions in a long-term setting according to the nature of the disease. The resulting progress will address functionally disabling manifestations affecting the hands (digital ulcers and arthritis), and compare the efficacy and safety of off-label drugs in the treatment of vital organ manifestations. Specifically, the DeSScipher project will evaluate (i) the utility of a combination of easy-to-perform clinical and laboratory investigations in combination with capillaroscopy for identifying SSc patients at risk for the development of digital ulcers at an early stage (ii) the prevention and treatment of digital ulcers and hand arthritis in order to improve long-term disability and quality of life, (iii) the efficacy of different immunosuppressive agents in attenuating or inhibiting pulmonary fibrosis, (iv) the optimal treatment options for reducing morbidity and mortality of pulmonary hypertension and severe heart disease in SSc. Based on the results of these observational trials, the DeSScipher project will develop evidence-based clinical guidelines for the future management of adult and juvenile SSc to be disseminated widely and rapidly to physicians and patients. Novel outcome measures will also be provided as a basis for future clinical trials.'
Introduzione (Teaser)
A European project is performing the biggest-ever multinational observational trial on systemic sclerosis. Upon its completion, scientists should have a better idea of the most effective treatment for this rare disease.
Altri progetti dello stesso programma (FP7-HEALTH)
NIDIAG (2010)
Syndromic approach to Neglected Infectious Diseases (NID) at primary health care level: an international collaboration on integrated diagnostic-treatment platforms
Read MoreMASTERSWITCH (2008)
Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices
Read More